5A+5R干预联合伐尼克兰对COPD患者戒烟效果及肺功能的影响

目的 探讨5A+5R干预联合伐尼克兰对慢性阻塞性肺疾病(COPD)患者戒烟效果及肺功能的影响.方法 将2017年1月～2018年6月收治的120例COPD患者随机分为2组,对照组(n=60)给予伐尼克兰口服,干预组(n=60)在此基础上给予5A+5R策略进行戒烟干预,共持续12周.比较两组患者随访1、3、6个月时的戒烟...

Effect of 5A+5R intervention combined with varnicrane on smoking cessation and pulmonary function in patients with COPD

Objective To explore the effect of 5 A+5 R intervention combined with varnicrane on smoking cessation and pulmonary function in patients with COPD. Methods 120 patients with COPD admitted from January 2017 to June 2018 were randomly divided into two groups. The control group(n=60) was given the oral administration of varnicrane, and the intervention group(n=60) was given the smoking cessation intervention with 5 A+5 R strategy, which both lasted for 12 weeks. The smoking cessation rates at follow-up of 1, 3 and 6 months, nicotine dependence test scale(FTND) scores, lung function and quality of life before and after intervention were compared between the two groups. Results At the follow-up of 3 and 6 months, the success rate of smoking cessation in the intervention group was significantly higher than that in the control group, and the FTND score was also significantly increased(P<0.05). Following up for 6 months, all pulmonary function indicators in the two groups were improved at different degrees. The levels of FVC, FEV1 and FEV1/FVC in the intervention group were significantly better than those in the control group(P<0.05). Following up for 6 months, respiratory symptoms, activity restriction and disease influence scores of SGRQ in the intervention group were significantly lower than those before intervention, and they were significantly lower than those in the control group(P<0.05). Conclusion 5 A+5 R intervention combined with varnicrane can improve the success rate of smoking cessation, improve pulmonary function and improve the quality of life in patients with COPD.